108 BioCapital Backs SedMed's Non-Electric Toilet Lift With $4M

108 BioCapital is leading a financing round in SedMed, Inc. with a $4 million investment, according to the announcement dated October 2, 2026. The stage of the round was not disclosed, and 108 BioCapital is the only named investor.

SedMed, based in Danbury, Conn., makes a non-electric toilet lift designed to help older adults and individuals with mobility limitations sit and stand more safely and independently, while reducing strain on caregivers. The non-electric design is the product's defining characteristic as described in the announcement.

The financing is intended to support SedMed's next phase of commercial growth and to expand access to the lift. The company laid out four specific uses for the proceeds: accelerating commercial expansion, growing its distribution and channel partnerships, advancing its intellectual property portfolio, and conducting additional hospital-based studies.

That list places distribution and clinical evidence alongside product commercialization rather than treating them as later-stage concerns. Growing channel partnerships suggests SedMed is looking to reach patients and caregivers through existing intermediaries rather than build a direct sales operation from scratch, while the commitment to further hospital-based studies indicates the company intends to keep generating clinical support as it scales.

The addressable audience SedMed describes is a broad one: older adults and people with mobility limitations, plus the caregivers who assist them. The company frames the lift's value in two directions at once — greater independence for the user, and less physical strain for the person helping them.

108 BioCapital's $4 million check arrives as the sole investment figure attached to the round in the announcement. No valuation, revenue figures, prior funding history or headcount were disclosed, and the company did not name a round stage.

What the announcement does make clear is the sequence SedMed and its new lead investor appear to be pursuing: convert the device's commercial momentum into wider distribution, deepen the patent position behind it, and keep adding hospital-based evidence to support adoption.